François Volery, Yara Banz, Alexander Heini, Marie-Noelle Kronig, Daniel Siegrist, Michael Daskalakis, Ulrike Bacher, Thomas Pabst
{"title":"Therapy-Related Acute Myeloid Leukemia after CAR-T Cell Therapy with Brexucabtagene Autoleucel for Mantle Cell Lymphoma.","authors":"François Volery, Yara Banz, Alexander Heini, Marie-Noelle Kronig, Daniel Siegrist, Michael Daskalakis, Ulrike Bacher, Thomas Pabst","doi":"10.1159/000541256","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The introduction of CAR-T cell treatment for relapsed/refractory (r/r) mantle cell lymphoma improved survival rates of these patients. Along with its introduction in clinical routine, long-term events after CAR-T cell treatment are increasingly emerging.</p><p><strong>Case presentation: </strong>We report the case of a patient developing acute erythroid leukemia with biallelic <i>TP53</i> inactivation occurring 26 months after CAR-T therapy with brexucabtagene autoleucel (brexu-cel) for r/r mantle cell lymphoma. The patient presented with a healthy bone marrow prior to lymphoma treatments.</p><p><strong>Discussion: </strong>Secondary malignancies seem more frequent after CAR-T therapies. More studies are needed to assess potential long-term toxicities of CAR-T cell therapies including the frequency of secondary myeloid malignancies.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1087-1093"},"PeriodicalIF":0.7000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521511/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000541256","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The introduction of CAR-T cell treatment for relapsed/refractory (r/r) mantle cell lymphoma improved survival rates of these patients. Along with its introduction in clinical routine, long-term events after CAR-T cell treatment are increasingly emerging.
Case presentation: We report the case of a patient developing acute erythroid leukemia with biallelic TP53 inactivation occurring 26 months after CAR-T therapy with brexucabtagene autoleucel (brexu-cel) for r/r mantle cell lymphoma. The patient presented with a healthy bone marrow prior to lymphoma treatments.
Discussion: Secondary malignancies seem more frequent after CAR-T therapies. More studies are needed to assess potential long-term toxicities of CAR-T cell therapies including the frequency of secondary myeloid malignancies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
